Contrasting of Biofrontera AG (BFRA) and Pacific Biosciences of California Inc. (NASDAQ:PACB)

This is a contrast between Biofrontera AG (NASDAQ:BFRA) and Pacific Biosciences of California Inc. (NASDAQ:PACB) based on their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biofrontera AG 11 0.00 10.31M -0.76 0.00
Pacific Biosciences of California Inc. 5 -0.24 149.42M -0.76 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Biofrontera AG and Pacific Biosciences of California Inc.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Biofrontera AG 95,817,843.87% 0% 0%
Pacific Biosciences of California Inc. 3,000,401,606.43% -102% -64.3%

Analyst Recommendations

The next table highlights the given recommendations and ratings for Biofrontera AG and Pacific Biosciences of California Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Biofrontera AG 0 0 1 3.00
Pacific Biosciences of California Inc. 0 1 1 2.50

Biofrontera AG’s upside potential is 77.51% at a $18 average price target. On the other hand, Pacific Biosciences of California Inc.’s potential upside is 55.64% and its average price target is $8. Based on the data given earlier, Biofrontera AG is looking more favorable than Pacific Biosciences of California Inc., analysts belief.

Institutional & Insider Ownership

Biofrontera AG and Pacific Biosciences of California Inc. has shares owned by institutional investors as follows: 2.04% and 77.7%. About 0.04% of Biofrontera AG’s share are owned by insiders. Insiders Competitively, owned 2.3% of Pacific Biosciences of California Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Biofrontera AG -5.81% -11.18% 28.16% 14% 2.71% 32.89%
Pacific Biosciences of California Inc. 1.89% -11.33% -26.93% -20.59% 52.97% -27.03%

For the past year Biofrontera AG had bullish trend while Pacific Biosciences of California Inc. had bearish trend.

Summary

Biofrontera AG beats on 7 of the 11 factors Pacific Biosciences of California Inc.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.